Effective flow-through polishing strategies for knob-into-hole bispecific antibodies

被引:6
作者
Chen, Serene W. [1 ]
Hoi, Kong Meng [1 ]
Bin Mahfut, Farouq [2 ]
Yang, Yuansheng [2 ]
Zhang, Wei [1 ]
机构
[1] Agcy Sci Technol & Res, Downstream Proc Grp, Bioproc Technol Inst, Singapore, Singapore
[2] Agcy Sci Technol & Res, Cell Line Dev Grp, Bioproc Technol Inst, Singapore, Singapore
关键词
Bispecific antibody; Knob-into-hole; Flow-through polishing; Host cell proteins; High molecular weight impurities; Low molecular weight impurities; Higher aggregation propensity; SINGLE-STEP PURIFICATION; MONOCLONAL-ANTIBODIES; LIGHT; CHROMATOGRAPHY; BLINATUMOMAB; MODULATION; EXCHANGE;
D O I
10.1186/s40643-022-00590-8
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Bispecific antibodies (bsAbs), though possessing great therapeutic potential, are extremely challenging to obtain at high purity within a limited number of scalable downstream processing steps. Complementary to Protein A chromatography, polishing strategies play a critical role at removing the remaining high molecular weight (HMW) and low molecular weight (LMW) species, as well as host cell proteins (HCP) in order to achieve a final product of high purity. Here, we demonstrate using two knob-into-hole (KiH) bsAb constructs that two flow-through polishing steps utilising Capto Butyl ImpRes and Capto adhere resins, performed after an optimal Protein A affinity chromatography step can further reduce the HCP by 17- to 35-fold as well as HMW and LMW species with respect to monomer by similar to 4-6% and similar to 1%, respectively, to meet therapeutical requirement at 30-60 mg/mL-resin (R) load. This complete flow-through polishing strategy, guided by Design of Experiments (DoE), eliminates undesirable aggregation problems associated with the higher aggregation propensity of scFv containing bsAbs that may occur in the bind and elute mode, offering an improved ease of overall process operation without additional elution buffer preparation and consumption, thus aligning well with process intensification efforts. Overall, we demonstrate that through the employment of (1) Protein A chromatography step and (2) flow-through polishing steps, a final product containing <1% HMW species,< 1% LMW species and < 100 ppm HCP can be obtained with an overall process recovery of 56-87%.
引用
收藏
页数:14
相关论文
共 60 条
  • [1] Allan B, 2014, Anti-tnf-anti-il-17 bispecific antibodies, Patent No. [WO2014137961A1, 2014137961]
  • [2] An Integrated Approach to Aggregate Control for Therapeutic Bispecific Antibodies Using an Improved Three Column Mab Platform-Like Purification Process
    Andrade, Cassia
    Arnold, Lindsay
    Motabar, Dana
    Aspelund, Matthew
    Tang, Alison
    Hunter, Alan
    Chung, Wai Keen
    [J]. BIOTECHNOLOGY PROGRESS, 2019, 35 (01)
  • [3] Baehner M, 2011, Bispecific, bivalent anti-vegf/anti-ang-2 antibodies, Patent No. [WO2011117329A1, 2011117329]
  • [4] Bispecific T-Cell Engaging Antibodies for Cancer Therapy
    Baeuerle, Patrick A.
    Reinhardt, Carsten
    [J]. CANCER RESEARCH, 2009, 69 (12) : 4941 - 4944
  • [5] Bertl S, 2015, Separation of bispecific antibodies and bispecific antibody production side products using hydroxyapatite chromatography, Patent No. [WO2015024896A1, 2015024896]
  • [6] The making of bispecific antibodies
    Brinkmann, Ulrich
    Kontermann, Roland E.
    [J]. MABS, 2017, 9 (02) : 182 - 212
  • [7] MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors
    Brischwein, K
    Schlereth, B
    Guller, B
    Steiger, C
    Wolf, A
    Lutterbuese, R
    Offner, S
    Locher, M
    Urbig, T
    Raum, T
    Kleindienst, P
    Wimberger, P
    Kimmig, R
    Fichtner, I
    Kufer, P
    Hofmeister, R
    da Silva, AJ
    Baeuerle, PA
    [J]. MOLECULAR IMMUNOLOGY, 2006, 43 (08) : 1129 - 1143
  • [8] Bruenker P, 2014, Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use, Patent No. [WO2014161845A1, 2014161845]
  • [9] Bispecific antibodies for cancer therapy The light at the end of the tunnel?
    Chames, Patrick
    Baty, Daniel
    [J]. MABS, 2009, 1 (06) : 539 - 547
  • [10] Excellent removal of knob-into-hole bispecific antibody byproducts and impurities in a single-capture chromatography
    Chen, Serene W.
    Hoi, Kong Meng
    Bin Mahfut, Farouq
    Yang, Yuansheng
    Zhang, Wei
    [J]. BIORESOURCES AND BIOPROCESSING, 2022, 9 (01)